Protocol ADX48621-301: Phase 2b/3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications

Objective

Clinical Trial Details >>

Principal Investigator(s)
Andrew Ridder, MD

Clinical Trial Categories

  • Parkinson’s
  • Neurology/Neurosurgery
Sponsor(s)
Addex Pharma S.A.
Contact
Avera Research Institute at 605-504-3154
or ARI@Avera.org

Location

  • Avera Brain & Spine Institute — Plaza 2
    1301 S Cliff Ave
    Plaza 2, Suite 610
    Sioux Falls, SD 57105
    Main: 605-322-7270
  • Avera Research Institute — Sioux Falls
    6001 S Sharon Ave
    Sioux Falls, SD 57108
    Main: 605-504-3154